Literature DB >> 20890314

Infection: Bismuth improves PPI-based triple therapy for H. pylori eradication.

Peter Malfertheiner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20890314     DOI： 10.1038/nrgastro.2010.131

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  9 in total

1.  Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report.

Authors:  P Malfertheiner; F Megraud; C O'Morain; F Bazzoli; E El-Omar; D Graham; R Hunt; T Rokkas; N Vakil; E J Kuipers
Journal:  Gut       Date:  2006-12-14       Impact factor: 23.059

2.  Editorial: Sequential therapy for eradication of Helicobacter pylori: a new guiding light or a false dawn?

Authors:  Paul Moayyedi; Peter Malfertheiner
Journal:  Am J Gastroenterol       Date:  2009-12       Impact factor: 10.864

3.  Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study.

Authors:  Rocco Maurizio Zagari; Gabriele Bianchi-Porro; Roberto Fiocca; Giovanni Gasbarrini; Enrico Roda; Franco Bazzoli
Journal:  Gut       Date:  2006-10-06       Impact factor: 23.059

4.  What is the optimal length of proton pump inhibitor-based triple therapies for H. pylori? A cost-effectiveness analysis.

Authors:  X Calvet; E Gené; T López; J P Gisbert
Journal:  Aliment Pharmacol Ther       Date:  2001-07       Impact factor: 8.171

5.  High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication.

Authors:  Qinjuan Sun; Xiao Liang; Qing Zheng; Wenzhong Liu; Shudong Xiao; Weiqi Gu; Hong Lu
Journal:  Helicobacter       Date:  2010-06       Impact factor: 5.753

Review 6.  Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.

Authors:  Luigi Gatta; Nimish Vakil; Gioacchino Leandro; Francesco Di Mario; Dino Vaira
Journal:  Am J Gastroenterol       Date:  2009-10-20       Impact factor: 10.864

7.  Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of colloidal bismuth subcitrate: clinical and in vitro studies.

Authors:  C S Goodwin; B J Marshall; E D Blincow; D H Wilson; S Blackbourn; M Phillips
Journal:  J Clin Pathol       Date:  1988-02       Impact factor: 3.411

8.  Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial.

Authors:  Loren Laine; Richard Hunt; Hala El-Zimaity; Bich Nguyen; Michael Osato; Jean Spénard
Journal:  Am J Gastroenterol       Date:  2003-03       Impact factor: 10.864

9.  Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication.

Authors:  Lorenzo Fuccio; Maria Eugenia Minardi; Rocco Maurizio Zagari; Diego Grilli; Nicola Magrini; Franco Bazzoli
Journal:  Ann Intern Med       Date:  2007-10-16       Impact factor: 25.391
  9 in total
  10 in total

1.  Selective killing of Helicobacter pylori with pH-responsive helix-coil conformation transitionable antimicrobial polypeptides.

Authors:  Menghua Xiong; Yan Bao; Xin Xu; Hua Wang; Zhiyuan Han; Zhiyu Wang; Yeqing Liu; Songyin Huang; Ziyuan Song; Jinjing Chen; Richard M Peek; Lichen Yin; Lin-Feng Chen; Jianjun Cheng
Journal:  Proc Natl Acad Sci U S A       Date:  2017-11-13       Impact factor: 11.205

2.  The diagnosis and management of H. pylori infection in Singapore.

Authors:  Claire Alexandra Zhen Chew; Tong Fong Lye; Daphne Ang; Tiing Leong Ang
Journal:  Singapore Med J       Date:  2017-05       Impact factor: 1.858

3.  Functional disruption of peroxiredoxin by bismuth antiulcer drugs attenuates Helicobacter pylori survival.

Authors:  Yuen-Yan Chang; Tianfan Cheng; Xinming Yang; Lijian Jin; Hongzhe Sun; Hongyan Li
Journal:  J Biol Inorg Chem       Date:  2017-03-30       Impact factor: 3.358

Review 4.  Efficacy and Safety of Quinolone-Containing Rescue Therapies After the Failure of Non-Bismuth Quadruple Treatments for Helicobacter pylori Eradication: Systematic Review and Meta-Analysis.

Authors:  Alicia C Marin; Olga P Nyssen; Adrian G McNicholl; Javier P Gisbert
Journal:  Drugs       Date:  2017-05       Impact factor: 9.546

5.  Quadruple therapy with moxifloxacin and bismuth for first-line treatment of Helicobacter pylori.

Authors:  Antonio Francesco Ciccaglione; Luigina Cellini; Laurino Grossi; Leonardo Marzio
Journal:  World J Gastroenterol       Date:  2012-08-28       Impact factor: 5.742

6.  Metallochaperone UreG serves as a new target for design of urease inhibitor: A novel strategy for development of antimicrobials.

Authors:  Xinming Yang; Mohamad Koohi-Moghadam; Runming Wang; Yuen-Yan Chang; Patrick C Y Woo; Junwen Wang; Hongyan Li; Hongzhe Sun
Journal:  PLoS Biol       Date:  2018-01-10       Impact factor: 8.029

Review 7.  Rifabutin for the Treatment of Helicobacter Pylori Infection: A Review.

Authors:  Javier P Gisbert
Journal:  Pathogens       Date:  2020-12-28

8.  Analysis of the prevalence of Helicobacter pylori infection and the effectiveness of eradication schemes in patients with the upper gastrointestinal tract disorders (according to the results of 13C-urea breath tests for 2006-2019).

Authors:  Nataliia Kondratiuk; Iryna Paliy; Serhii Zaika
Journal:  Prz Gastroenterol       Date:  2021-09-17

Review 9.  Optimization Strategies Aimed to Increase the Efficacy of Helicobacter pylori Eradication Therapies with Quinolones.

Authors:  Javier P Gisbert
Journal:  Molecules       Date:  2020-11-02       Impact factor: 4.411

10.  Experience with Rifabutin-Containing Therapy in 500 Patients from the European Registry on Helicobacter pylori Management (Hp-EuReg).

Authors:  Olga P Nyssen; Dino Vaira; Ilaria Maria Saracino; Giulia Fiorini; María Caldas; Luis Bujanda; Rinaldo Pellicano; Alma Keco-Huerga; Manuel Pabón-Carrasco; Elida Oblitas Susanibar; Alfredo Di Leo; Giuseppe Losurdo; Ángeles Pérez-Aísa; Antonio Gasbarrini; Doron Boltin; Sinead Smith; Perminder Phull; Theodore Rokkas; Dominique Lamarque; Anna Cano-Català; Ignasi Puig; Francis Mégraud; Colm O'Morain; Javier P Gisbert
Journal:  J Clin Med       Date:  2022-03-16       Impact factor: 4.241
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.